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Abstract The aim was to investigate the immunoreac-
tivities for NOS enzymes in frontal cortex and meningeal
vessels after chemical stimulation of the subarachnoid
space of adolescent rats and the effect of sumatriptan pre-
treatment on the immunoreactivities of the NOS enzymes.
Male adolescent Wistar rats were used. Rats in group 1 did
not taken intracisternal injection. Rats in group 2 were taken
intracisternal autologous blood injection, but no sumatrip-
tan pre-treatment. Rats in group 3 were taken intracisternal
autologous blood injection, but they were taken sumatriptan
pre-treatment. Tissue samples were investigated for the
presence of NOS immunoreactivity. The mean values of
immunolabeling intensities for NOS enzymes in frontal
cortex and meningeal vessels were significantly increased
in group 2 compared to group 1. The mean values of
immunolabeling intensities for NOS enzymes in frontal
cortex and meningeal vessels were significantly reduced in
group 3 compared to group 2. These results suggest that,
chemical stimulation of the subarachnoid space increased
the immunoreactivities of NOS enzymes in the brain of
adolescent rats. The increased NOS immunoreactivities
could be antagonized by pre-treatment with sumatriptan.
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Introduction
Migraine is the most common primary headache syndrome
during childhood and adolescence [1]. However, the
pathophysiology of migraine is not fully understood. The
proposed theory for classical migraine pathophysiology is
the trigeminovascular theory. The propagation of the cor-
tical-spreading depression to the pain-sensitive trigeminal
sensory fibers is believed to induce the headache [2–4].
Stimulation of the trigeminal sensory neurons results in the
release of a number of vasoactive substances such as cal-
citonin gene-related peptide (CGRP), vasoactive intestinal
peptide (VIP) and substance P (SP), which induce vascular
dilatation and neurogenic inflammation [5–7]. In recent
years, many studies demonstrated the participation of nitric
oxide (NO) in the pathogenesis of headache. NO is formed
from the amino acid L-arginine by nitric oxide synthases
(NOS), namely endothelial NOS (eNOS), neuronal NOS
(nNOS) and inducible NOS (iNOS). eNOS and nNOS are
constitutively expressed in endothelial cells and neurons,
respectively, and their expression is the object of regulation
at the transcriptional, translational and post-translational
levels. The synthesis of iNOS is induced by endotoxin and
by inflammatory cytokines in macrophages and many other
cell types [8]. It has been reported that NO plays an active
role in dural vasodilatation, contributing to the pathogen-
esis of migraine. NO causes migraine-like headache in both
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control volunteers and headache patients that fulfills the
International Headache Society criteria for migraine in
sufferers for several hours after NO infusion [9–12]. But it
is scarce if NOS enzymes are activated after stimulation of
the trigeminal sensory neurons.
The well-known 5-HT1B/1D serotonin receptor agonist
sumatriptan is commonly prescribed for the treatment of
acute migraine attack. The therapeutic action of suma-
triptan is thought to be consistent with neuronal
inhibition. It was shown that sumatriptan could inhibit
neurogenic meningeal dural vasodilatation caused by
electrical stimulation. This action was thought to be via
the inhibition of the release of CGRP from trigeminal
sensory fibers innervating the cranial blood vessels [13–
15]. However, it is unclear if sumatriptan has any effect
on NOS enzymes.
The aim of this study was to investigate the immuno-
reactivity for NOS enzymes in meningeal vessels and
frontal cerebral cortex after the chemical stimulation of
the subarachnoid space of adolescent rats and the effect
of sumatriptan on the immunoreactivity for the NOS
enzymes.
Materials and methods
The study protocol was approved by the Ethical Committee
of Dokuz Eylu¨l University Medical School (permit
no:113-2006).
Animals
Male adolescent Wistar rats (Dokuz University School of
Medicine, Izmir, Turkey) weighing 90–120 g were used.
Animals were housed in an appropriate cage on a 12-h
light/12-h dark cycle with free access to standard labora-
tory food and tap water. The animals were allowed to
habituate to the housing facilities for at least 1 week before
the starting of experiments. They were divided into three
groups of seven animals each:
Group 1 served as the sham rats which were anaesthe-
tized and catheterized but were not administered
intracisternal autologous blood injection.
Group 2 served as the control rats which were anaes-
thetized, catheterized and administered 0.1 mL intra-
cisternal autologous blood injection, but were not given
sumatriptan pretreatment. Instead of sumatriptan, they
were given physiological saline of the same volume
intraperitoneally.
Group 3 was the study group, which were anaesthetized,
catheterized and treated with sumatriptan succinate
(0.3 mg kg-1 body weight, intraperitoneally) 2 h before
intracisternal autologous blood injection [16].
Procedures
Rats were anaesthetized with sodium pentobarbital
(45 mg kg-1 body weight, intraperitoneally). As previ-
ously reported, a midline skin incision was performed from
the occipital protuberance to cervical area [17]. Skin and
soft tissue overlying the skull were removed and a catheter
was introduced into the cisterna magna. In groups 2 and 3,
0.1 mL autologous blood was injected into the cisterna
magna over about 1 min through the catheter. The rats
were kept in a horizontal prone position for 30 min in order
to facilitate the settling of blood in the basal cisterns. Sham
animals were treated identically but received no intracis-
ternal injection or sumatriptan pretreatment. Rats were
killed at 1 h after intracisternal blood instillation.
Tissue processing, histology
and immunohistochemistry
At the end of the experiment, brain tissues of rats were
removed. Tissue samples were fixed in 10% formalin in
phosphate buffer, processed by routine histological meth-
ods and embedded in paraffin blocks. Sections were cut by
a microtome (Leica RM2255), and eNOS and nNOS
immunohistochemistry was performed using an anti-eNOS
(GeneTex, Inc.), and anti-nNOS (StressGen Biotechnologies
Corp., Canada) antibodies. Sections were deparaffinized in
xylene, and rehydrated through a graded ethanol series.
They were then treated with 2% trypsin at 37C for 15 min.
Sections were incubated in a solution of 3% H2O2 for
15 min to inhibit endogenous peroxidase activity. The
sections were incubated overnight with anti-eNOS and
anti-nNOS antibodies and then for another 30 min with
the biotinylated mouse secondary antibody. The bound
secondary antibody was then amplified with Vector Elite
ABC kit (Vectastain, Vector Laboratories, Burlingame,
CA, USA). The antibody-biotin-avidin-peroxidase com-
plexes were visualized using 0.02% DAB and nuclei were
counterstained with Harris hematoxylin. The sections were
finally mounted onto lysine-coated slides. The images were
analyzed by using a computer-assisted image analyzer
system consisting of a microscope (Olympus BX-50,
Tokyo, Japan) equipped with a high-resolution video
camera (JVC TK-890E, Japan). The immunolabeling
scores were evaluated blindly. Immunolabeling intensity
was graded as mild (1), moderate (2), strong (3) and very
strong (4) [18].
Statistical analysis
All the statistical analyses were performed using computer
program SPSS version 15 for windows (SPSS, Chicago, IL,
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USA). Results are presented as mean ± SEM. All data
were analyzed by one-way analysis of variance (ANOVA)
post hoc Bonferroni test. P \ 0.05 was considered statis-
tically significant.
Results
In animals which received 0.1 ml of autologous blood into
the cisterna magna, extensive clots were observed over the
surface of the forebrain including the basal cisterns and the
cisterns surrounding the basal cisterns. Immunohisto-
chemical evaluation based on the intensities of eNOS and
nNOS immunoreactivities in the brain tissue of frontal
cortex is shown in Tables 1 and 2. Microphotographs of
eNOS and nNOS immunoreactivities in frontal cortex are
shown in Fig. 1. The mean values of the parenchymal
eNOS immunolabeling intensities in the sham (group 1),
control (group 2) and study (group 3) animals were
1.28 ± 0.48, 3.57 ± 0.53 and 2.57 ± 0.53, respectively
Table 1 The comparison of the
immune staining in frontal
cortex with eNOS antibodies
between the sham, study and
sumatriptan pretreatment groups
* Comparison between groups 1 and 2 













eNOS 1.28 ± 0.48 3.57 ± 0.53 2.57 ± 0.53 0.010
   000.0=p* 
 600.0=p**  
Table 2 The comparison of the
immune staining in frontal
cortex with nNOS antibodies
between the sham, study and
sumatriptan pretreatment groups
* Comparison between groups 1 and 2 













nNOS 1.14 ± 0.37 3.28 ± 0.75 2.14 ± 0.69 0.019
   000.0=p* 
 010.0=p**  
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(P = 0.010). The mean values of the parenchymal nNOS
immunolabeling intensities in the sham (group 1), control
(group 2) and study (group 3) animals were 1.14 ± 0.37,
3.28 ± 0.75, 2.14 ± 0.69, respectively (P = 0.019).
According to the scoring system, the intensities of eNOS
and nNOS immunolabeling in group 2 were found to have
significantly increased compared to group 1 (P = 0.000,
P = 0.000 respectively). The immunoreactivities for eNOS
and nNOS in frontal cortex was significantly reduced in
group 3 (animals treated with sumatriptan) when compared
to group 2 (P = 0.006, P = 0.010, respectively).
In meningeal vessels, numerous eNOS positive cells
were seen after blood injection to the cisterna magna.
Microphotographs of eNOS immunoreactivity in menin-
geal vessels are shown in Fig. 2. Immunohistochemical
evaluation based on the intensities of eNOS immunoreac-
tivity in meningeal vessels is demonstrated in Table 3. The
mean values of the eNOS immunolabeling intensities in the
sham (group 1), control (group 2) and study (group 3)
animals were 1.28 ± 0.48, 3.42 ± 0.78, 2.14 ± 0.69,
respectively (P = 0.000). In group 2, the immunoreactivity
for eNOS was significantly increased when compared to
group 1 (P = 0.000). The immunoreactivity for eNOS in
meningeal vessels was significantly reduced in group 3
(animals treated with sumatriptan) when compared to
group 2 (P = 0.006).
Discussion
Animal models have been extremely helpful to understand
the migraine pathophysiology and in developing new
therapeutic approaches [19]. It is noteworthy that almost all
experimental studies in the field of primary headache
research were performed in adult animals. On the other
hand, primary headaches are not only the subject of the
Fig. 1 Representative photomicrographs showing immunolabeling of
eNOS and nNOS in the cerebral cortex of rats. a–c Show sections of
sham, study (group II) and sumatriptan pretreatment groups (group
III), respectively. Above photomicrographs of eNOS staining by
immunohistochemistry. Below photomicrographs of nNOS staining
by immunohistochemistry (as indicated by the asterisks). Significant
positive immunolabeling was detectable in tissues from group II
animals and a slight immunolabeling in group III (920)
Fig. 2 Photomicrographs of eNOS staining by immunohistochemis-
try in the capillary endothelial cells. There was no eNOS
immunoreactivity in sham group (a). The sections of group II
animals showed more intense labeling (b) and a slight eNOS
immunoreactivity was observed in group III (c) (9100)
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adult people but also the adolescents and children also
suffer from migraine, and it is well known that adult data
did not always reflect the case of young people. In the
literature, information is lacking about the pathophysiology
of migraine headache in adolescent animals. We propose
that our results might be helpful in understanding of the
complex pathophysiology of migraine and in reflecting the
data of the adolescents.
It has been demonstrated that chemical or electrical
stimulation of the dura mater or of cranial blood vessels
reproduces signs of migrainous pain. Electrical stimulation
of the superior sagittal sinus in the cat leads to increased
metabolic activity in the trigeminal nucleus caudalis and in
the C2 region of the spinal cord [20]. Other studies also
demonstrated a marked increase of the immediate early
gene c-fos in laminae I and II of the trigeminal nucleus
caudalis and the superficial layers of the C1 and C2 regions
after stimulation of the middle meningeal artery, the
superior sagittal sinus or the trigeminal ganglion in mon-
keys and cats [21–23]. Blood or blood products are the
most likely stimulus of meningeal afferents, and in this
regard, the instillation of homologous blood into the cis-
terna magna is used as an experimental model for migraine
headache [19]. Earlier studies have investigated the path-
ophysiology of migraine in such a model of adult rats. It
has been shown that blood in the subarachnoid space is an
effective stimulus for activating the c-fos expression within
subpopulations of brainstem neurons [17, 24]. We adapted
this experimental model to adolescent rats. In the study
presented here, autologous blood injected intracisternally
was used for the stimulation of the trigeminovascular
system. We thought that the significantly increased NOS
immunoreactivities in meningeal vessels and frontal cortex
of the animals demonstrate the efficient stimulus of autol-
ogous blood on the trigeminovascular system.
In recent years, immunohistochemical methods have
begun to allow a better understanding the trigeminocervical
interactions and inflammatory activation of the trigemino-
vascular system. The nerve cell bodies of the trigeminal
ganglion express various neurotransmitters including
CGRP, SP, PACAP and NO [25]. There is evidence that
the turnover of the neuropeptides such as CGRP and SP
increases after blood is injected into the subarachnoid
space. However, the mechanisms by which trigeminal
afferent axons become activated are not well understood
[17]. NO has been proposed to be a key molecule in
migraine. Experimental evidence suggests its intervention
in vasodilatation and activation of the trigeminovascular
system and its implication in coupling neuronal and vas-
cular changes during spreading depression [9]. In our
study, numerous NOS immunoreactive cells were observed
in response to the injection of blood in meningeal vessels
and brain parenchyma. These data support that NOS
enzymes are activated after trigeminovascular stimulation.
In our study, we investigated the immunoreactivity of
eNOS and nNOS enzymes in the brain parenchyma and
meningeal vessels of the adolescent rats. iNOS is the
inducible isoform of NOS enzymes. It has been reported
that iNOS requires a delay of 6–8 h before the onset of NO
production [26]. Because iNOS is not constitutively
expressed in neurons or endothelial cells, we did not
investigate the presence of iNOS immunoreactivity. Newer
Table 3 The comparison of the
immune staining in meningeal
vessels with eNOS antibodies














eNOS 1.28 ± 0.48 3.42 ± 0.78 2.14 ± 0.69 0.000
   000.0=p* 
  600.0=p**  
* Comparison between groups 1 and 2 
** Comparison between groups 2 and 3 
J Headache Pain (2008) 9:317–323 321
123
studies demonstrated the iNOS expression in central ner-
vous system and in microglia cells [27, 28]. We thought
that, iNOS immunoreactivity might be investigated in the
future studies of migraine using further experimental
methods.
The mechanism of action of anti-migraine compounds is
of interest in the context of developing new treatment
strategies. Experimental studies demonstrated a marked
increase of the immediate early gene c-fos in laminae I and
II of the trigeminal nucleus caudalis and the superficial
layers of the C1 and C2 regions after stimulation of the
middle meningeal artery, the superior sagittal sinus or the
trigeminal ganglion in monkeys and cats [21–23]. This
response is reduced by anti-migraine agents, such triptans
[29–31]. It has been shown that, both in vitro and in vivo,
5-HT1B binding sites are present in very low concentration
in trigeminal nucleus caudalis and cervical dorsal horn,
below 12% of total specific sumatriptan binding. Similarly,
5-HT1D receptors also account for about 50% of the total
specific binding [32]. These results gave weight to the
proposal that antimigraine action of sumatriptan could in
part be exerted via other mechanisms. It has been reported
that sumatriptan inhibits the NO response by inhibiting
trigeminal activation and CGRP release [33]. Similarly, it
has been suggested that triptans prevent the release of
CGRP from perivascular nerve terminals in the dura mater
by an action at 5-HT1B/1D receptors [34]. Suwattanasophon
et al. have shown that sumatriptan pretreatment attenuated
the nitroglycerin-evoked expression of nNOS in trigeminal
ganglia, trigeminal nucleus caudalis and perivascular nerve
fiber surrounding superior sagittal sinus of the rats. They
suggested that 5-HT1B/1D receptor has an important role in
stabilizing the trigeminovascular system by attenuating the
expression of nNOS enzyme and reducing nitric oxide
production [35]. In our study, it was determined that su-
matriptan administered 2 h before intracisternal autologous
blood injection significantly reduced the intensity of
increased eNOS immunolabeling both in brain parenchyma
and meningeal vessels, and nNOS immunolabeling in brain
parenchyma of the adolescent rats. It has been reported that
the density of 5-HT1B receptors are found to be increased
in the frontal cortex in the rat brain [36]. With the aim to
identify the effect of sumatriptan, the immunoreactivities
of the NOS enzymes were investigated both in the frontal
cortex and the meningeal vessels in our study. We specu-
lated that sumatriptan had an inhibitory effect on the
release of the NOS enzymes in adolescent rats. But the
understanding of the mode of this action needs further
investigation.
In conclusion, chemical stimulation of the meninges
using autologous blood in adolescent rats increased the
immunoreactivities of eNOS and nNOS enzymes in the
frontal cortex and of eNOS enzyme in meningeal vessels,
and thereby the formation of NO in brain parenchyma and
meningeal vessels. Pretreatment with the antimigraine
drug, sumatriptan, prevented the immunoreactivities of
eNOS and nNOS enzymes in the meningeal vessels and the
frontal cortex of the adolescent rats. These results indicate
the participation of NOS enzymes in migraine pathophys-
iology and suggest that, in the future, specific NOS enzyme
inhibitors could serve as pharmacological agents to treat
migraine headache.
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